Recently, Med 7 LLC, and HempCo Inc., announce the publication of the first prospective human clinical trial using a CBD rich Full Spectrum Hemp Oil in patients with COVID-19.
“These findings are very relevant since cytokine levels and WBC counts on admission significantly correlate with death in COVID patients,” according to David Cooper, MD, PhD, one of the authors of the study.
“There have been two recently published studies on the effects of CBD and other cannabinoids on COVID. These studies are important in looking at the effects of cannabinoids on COVID replication and cellular entry,” continued Cooper.
“Both of these previous studies were conducted on human and primate cell lines in laboratories. This current study is the first randomized prospective study of a CBD rich product in human subjects with active COVID infection.”